All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Long term safety and efficacy results of ibrutinib use in CLL patients

By Sara Valente

Share:

Mar 16, 2018


On 8 February 2018, long term safety and efficacy study results of ibrutinib use in patients with chronic lymphocytic leukemia (CLL) were published online in Blood. The study by Susan O’Brien, University of Texas MD Anderson Cancer Center, and the University of California, and colleagues, highlighted outcomes in relapsed/refractory (R/R) and treatment-naïve (TN) patients after a follow-up of 5 years.

Study Overview

  • N = 132 patients included in the study, either TN (n = 31) or R/R (n = 101)
  • Treatment dose was 420 or 840mg ibrutinib orally once daily
  • The primary endpoint of the study was safety and secondary endpoints included overall response rate (ORR), complete response (CR), progression-free survival (PFS) and overall survival (OS)

Safety

  • Median time on treatment; TN = 65 months and R/R = 39 months
  • Discontinuation of treatment occurred in 72% of R/R patients (disease progression 33% and adverse events (AEs) 21%) and 45% of TN patients (disease progression 6% and AEs 19%)
  • Most common ≥3 AEs for TN vs R/R = hypertension (32% vs 25%), pneumonia (10% vs 27%), neutropenia (3% vs 21%), thrombocytopenia (3% vs 11%) and atrial fibrillation (6% vs 9%)
  • Analysis showed that R/R patients with unmutated IGHV and CK were more likely to discontinue treatment. Additionally, discontinuation rates were not affected by del(11q)

Efficacy

  • Median time on study = 61.5 months (0.7–75.2)
  • Efficacy results described as TN vs R/R:
    • Median PFS = not reached (NR) vs 51 months
    • 5-year estimated PFS = 92% vs 44%
    • Median OS = NR vs NR
    • 5-year OS = 92% vs 60%
    • Median duration of response (DOR) = 72.8 months vs 57
    • ORR = 87% (95% CI, 70.2–96.4%) vs 89% (95% CI, 81.3–94.4%)
    • CR = 29% vs 10%
    • Disease progression at 5-year follow-up = 3% vs 36%
  • Patients with del(11q) and CK had a shorter DOR. The authors also found that patients with del(17p) and CK had shorter median PFS and OS. In further analysis, it was also found that patients with CK and del(17p) had lower ORR, DOR, median PFS and OS compared to those with just CK
  • Patients with fewer lines of therapy (1–3) experienced better ORR and median DOR

The authors concluded that ibrutinib as a single agent showed long term efficacy and durable responses with an acceptable safety profile in patients with CLL. Similar results were also reflected in another long term follow-up study with ibrutinib in CLL patients by Inhye Ahn et al. The study authors found that ibrutinib also demonstrated durable responses after 5 years in TN and R/R CLL patients.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?